Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eukaryotic translation termination factor 1 (eRF1) is an essential protein involved in the recognition of stop codons (UAA, UAG, UGA) during mRNA translation, and catalyzes the release of newly synthesized polypeptides from the ribosome. eRF1 functions as part of a complex with eRF3 and GTP, and is required for accurate termination of translation and for nonsense-mediated mRNA decay (NMD), which eliminates mRNAs with premature stop codons. The structure of eRF1 consists of three domains that collectively mimic tRNA, allowing eRF1 to fit into the ribosomal A-site and interact with the peptidyl transferase center to hydrolyze peptidyl-tRNA. Proper functioning of eRF1 is critical for cellular viability, with mutations in key motifs (such as the GGQ loop) leading to loss of function and cell death. eRF1 is highly conserved among eukaryotes and has functional homologs in archaea, with distinct evolutionary differences from prokaryotic release factors[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation termination factor 1 (eRF1).